Clinical trial
COMBISTRAT: AmBisome® in Combination With Caspofungin for the Treatment of…
NCT00334412 · Gilead Sciences, Industry · Completed
Key facts
| NCT number | NCT00334412 |
|---|---|
| Title | COMBISTRAT: AmBisome® in Combination With Caspofungin for the Treatment of Invasive Aspergillosis |
| Official title | AmBisome® in Combination With Caspofungin Versus AmBisome® High Dose Regimen for the Treatment of Invasive Aspergillosis in Immunocompromized Patients: Randomized Pilot Study. |
| Lead sponsor | Gilead Sciences, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Invasive Aspergillosis |
| Intervention type | Drug |
| Interventions | Ambisome, caspofungin |
| Enrollment | 30 |
| Start date | Mar 1, 2004 |
| Completion | May 1, 2006 |
| First posted | Jun 7, 2006 |
| Last update posted | Jul 9, 2015 |
| Countries | France |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: